Phase 2 clinical trial of temelimab against neuropsychiatric syndromes of Post-COVID :
Recruitment completed in November 2023;
Topline results planned for end of June 2024.
Cash position.
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
A Swiss joint stock company with share capital of 1,249,951.40 Swiss francs Registered and principal office: 3 chemin du Pré-Fleuri - 1228 Plan-les-Ouates. | April 30, 2023
The EIB and GeNeuro Sign a EUR 25 Million Credit Line Backed by InvestEU to Support Clinical Developments Against Long-COVID streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.